当前位置: 首页 > 期刊 > 《今日健康》 > 2015年第8期
编号:12842436
预防性使用唑来磷酸对绝经后乳腺癌来曲唑治疗患者骨密度减少研究(2)
http://www.100md.com 2015年8月1日 《今日健康》 2015年第8期
     [3]GOSS PE, INGLE JN, MARTINO S, et al. Randomized trial ofletrozole following tamoxifen as extended adjuvant therapy in re-ceptor- positive breast cancer: updated findings from NCIC CTGMA.17[J]. J Natl Cancer Inst. 2005,97(17):1262- 71.

    [ 4] 江泽飞, 宋三泰, 刘晓晴, 等. 369 例 E R 阳性乳腺癌辅助内分泌治疗的前瞻性临床研究[ J ] . 中华肿瘤杂志, 2001, 23( 5) :420-422.

    [4] Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: anupdate on mechanisms of action and how these relate to clinicalefficacy [J] . Ann N Y Acad Sci, 2007, 1117(11): 209-257.

    [5] 孙晶波,任云会.唑来磷酸联合芳香化酶抑制剂治疗绝经后乳腺癌骨转移的疗效观察[J].齐齐哈尔医学院学报,2014,15(11):56-57.

    [6] J Roelofs A , Thompson K , H Ebetino F , et al. Bisphos-phonates : molecular mechanisms of action and effects onbone cells , monocytes and macrophages[J]. Curr Pharm Des ,2010 , 16(27) : 2950-2960

    [7] Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrinetherapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12randomised trial [J] . Lancet Oncol, 2011, 12(7): 631-641., http://www.100md.com(罗盘 翁洁 文芳 肖佳)
上一页1 2